Identification of MOAG-4/SERF as a Regulator of Age-Related Proteotoxicity  by van Ham, Tjakko J. et al.
Identification of MOAG-4/SERF as a
Regulator of Age-Related Proteotoxicity
Tjakko J. van Ham,1,5,6 Mats A. Holmberg,1,5 Annemieke T. van der Goot,1,5 Eva Teuling,1,5 Moises Garcia-Arencibia,2
Hyun-eui Kim,3 Deguo Du,4 Karen L. Thijssen,1 Marit Wiersma,1 Rogier Burggraaff,1 Petra van Bergeijk,1
Jeroen van Rheenen,1 G. Jerre van Veluw,1,7 Robert M.W. Hofstra,1 David C. Rubinsztein,2 and Ellen A.A. Nollen1,*
1Department of Genetics, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands
2Cambridge Institute for Medical Research, Department of Medical Genetics, University of Cambridge Wellcome Trust/MRC Building,
Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0XY, UK
3The Salk Institute for Biological Studies, Molecular and Cell Biology Laboratory, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA
4Departments of Chemistry and Molecular and Experimental Medicine and The Skaggs Institute of Chemical Biology, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
5These authors contributed equally to this work
6Present address: Cardiovascular Research Center, Massachusetts General Hospital, HarvardMedical School, 149 13th Street, Charlestown,
MA 02129, USA
7Present address: Department of Biology, University of Utrecht, Padualaan 8, 3584 CH Utrecht, the Netherlands
*Correspondence: e.a.a.nollen@medgen.umcg.nl
DOI 10.1016/j.cell.2010.07.020SUMMARY
Fibrillar protein aggregates are themajor pathological
hallmark of several incurable, age-related, neurode-
generative disorders. These aggregates typically
contain aggregation-prone pathogenic proteins,
such as amyloid-beta in Alzheimer’s disease and
alpha-synuclein inParkinson’s disease. It is, however,
poorly understood how these aggregates are formed
during cellular aging. Here we identify an evolution-
arily highly conserved modifier of aggregation,
MOAG-4, as a positive regulator of aggregate forma-
tion in C. elegansmodels for polyglutamine diseases.
Inactivation of MOAG-4 suppresses the formation of
compact polyglutamine aggregation intermediates
that are required for aggregate formation. The role of
MOAG-4 in driving aggregation extends to amyloid-
beta and alpha-synuclein and is evolutionarily
conserved in its human orthologs SERF1A and
SERF2. MOAG-4/SERF appears to act independently
from HSF-1-induced molecular chaperones, protea-
somal degradation, and autophagy. Our results
suggest that MOAG-4/SERF regulates age-related
proteotoxicity through a previously unexplored
pathway,whichwill openupnewavenues for research
on age-related, neurodegenerative diseases.INTRODUCTION
Fibrillar aggregates of aggregation-prone proteins are a hallmark
of several aging-associated neurodegenerative disorders,
including Parkinson’s, Huntington’s, and Alzheimer’s diseases
(Chiti and Dobson, 2006; Goedert and Spillantini, 2006;Scherzinger et al., 1997; Spillantini and Goedert, 2000). These
aggregates typically contain amyloid-like fibrils composed of
disease-specific aggregation-prone proteins, such as mutant
huntingtin protein in Huntington’s disease and alpha-synuclein
in Parkinson’s disease. The role of these aggregates in disease
is still controversial: whereas the aggregates were initially
thought to be pathogenic, more recent studies suggest that
they have a protective role (Arrasate et al., 2004; Nagai et al.,
2007; Sanchez et al., 2003; Saudou et al., 1998; Schaffar et al.,
2004; Caughey and Lansbury, 2003; Haass and Selkoe, 2007;
Kayed et al., 2003). Aggregation properties do appear to be
required for pathogenesis, however, because inhibition of intra-
molecular aggregation and oligomerization suppresses toxicity
(Nagai et al., 2007; Sanchez et al., 2003; Saudou et al., 1998;
Schaffar et al., 2004). Thus, microscopically invisible, soluble,
misfolded monomers and oligomeric precursors of aggregates
are proposed as pathogenic structures (Nagai et al., 2007;
Sanchez et al., 2003; Saudou et al., 1998; Schaffar et al., 2004).
The current view of how cells cope with misfolded and aggre-
gation-prone proteins is that they are either refolded by molec-
ular chaperones or degraded by the proteasome and other
proteases (Ravikumar et al., 2004; Rubinsztein, 2006; Bukau
et al., 2006; Goldberg, 2003). When these quality control mech-
anisms are overwhelmed or functionally impaired, which may
occur in response to environmental stresses, during aging, and
in disease, cells are thought to protect themselves against
toxicity by sequestering aggregation-prone proteins, compactly
folded, in aggregates (Hsu et al., 2003; Kaganovich et al., 2008;
Kopito, 2000; Muchowski et al., 2002; Nollen et al., 2001;
Williams and Paulson, 2008; Yamamoto et al., 2000).
How protein aggregates are formed and how this process is
influenced by cellular aging and hereditary factors is unknown.
One previously identified genetic suppressor of protein
aggregation that links the process of aging and polyglutamine
aggregation in a C. elegans model for disease is the longevity
gene age-1 (Morley et al., 2002). AGE-1 is a PI3 kinase in theCell 142, 601–612, August 20, 2010 ª2010 Elsevier Inc. 601
insulin/IGF-1-like signaling (IIS) pathway, which negatively
regulates downstream transcription factors DAF-16/FOXO
and HSF1 (Hsu et al., 2003; Morley and Morimoto, 2004; Ogg
et al., 1997; Tissenbaum and Ruvkun, 1998). Reduced activity
of the IIS pathway leads to activation of DAF-16 and HSF-1,
which drive expression of a variety of longevity-promoting
genes, including molecular chaperones with a role in preventing
protein misfolding and aggregation (Cohen et al., 2006; Cohen
and Dillin, 2008).
With C. elegans models for protein conformational diseases
and genome-wide RNAi screens for genetic modifiers of protein
aggregation, we have previously identified genes encoding
proteins with roles in protein synthesis, protein folding, protein
degradation, and vesicle trafficking and genes encoding
proteins with no predicted function that when depleted increase
the number of aggregates. These screens have revealed that
a complex network of processes is involved in maintaining
protein homeostasis (Nollen et al., 2004; van Ham et al., 2008).
These modifiers include proteins with a confirmed role in
modifying the toxicity of aggregation-prone proteins in human
cell models, including HSP70 and cytosolic chaperonins
(Behrends et al., 2006; Kitamura et al., 2006; Muchowski et al.,
2000; Tam et al., 2006). These findings have indicated the evolu-
tionary conservation of these protein quality control pathways
and have exemplified the strength of using C. elegans to find
genetic modifiers that may be relevant for human neurodegener-
ative diseases.
Here, we performed a chemical mutagenesis screen for genes
encoding proteins with the opposite function, which upon muta-
tion suppress protein aggregation. We identified modifier of
aggregation 4 (MOAG-4), which is homologous to SERF1A and
SERF2 in humans. Our results suggest that inactivation of
MOAG-4 suppresses proteotoxicity via a previously unexplored
pathway.
RESULTS
Loss ofmoag-4 Suppresses Polyglutamine Aggregation
To identify genes involved in the formation of aggregates, we
used a C. elegans model for protein conformational diseases.
This model expresses a polypeptide of 40 glutamine residues
fused to yellow fluorescent protein (Q40::YFP), hereafter referred
to as Q40 animals (Morley et al., 2002). One previously identified
suppressor of protein aggregation inC. elegans is a loss-of-func-
tion mutation in the life-span-regulating gene age-1 (Morley
et al., 2002). We found that age-1(hx546), hereafter referred to
as age-1 mutant, suppressed aggregation of Q40::YFP by 30%
(Figure 1A).
Wemutagenized Q40 animals to screen formodifiers of aggre-
gation (moag) that showed suppression of aggregation similar or
stronger than in age-1 mutant animals and identified moag-4
(pk2185), hereafter referred to as moag-4 point mutant, which
showed a 75% reduction in the number of aggregates (Figures
1A and 1E). The mutation in moag-4 mapped to the gene
Y37E3.4 (accession number: NM_058523) (Figure 1B), which
encodes a small protein of unknown function that is evolution-
arily highly conserved (Figure 1C). MOAG-4 (accession number:
NP_490924) contains a 4F5 domain of unknown function. It is602 Cell 142, 601–612, August 20, 2010 ª2010 Elsevier Inc.predicted to have a helix-loop-helix secondary structure
(Figure S1 available online). Although MOAG-4 has an
abundance of positively charged amino acid residues, which is
common for DNA- or RNA-binding domains, the DISIS algorithm
suggests that interactions with nucleic acids are unlikely,
although these cannot be excluded (Ofran et al., 2007; Ofran
and Rost, 2003). The G210A mutation is a missense mutation
in a strongly conserved amino acid residue, changingmethionine
at position 49 into an isoleucine (M49I) (Figure 1C). Human ortho-
logs of MOAG-4 are SERF1A (accession number:
NP_001171558) and SERF2 (accession number: AAC63516),
which show 50% and 54% amino acid similarity to MOAG-4.
These human orthologs are predicted by the ISIS algorithm to
have a conserved secondary structure (data not shown) (Rost
and Sander, 1993).
We confirmed that mutant moag-4 was responsible for
suppressing aggregation, by injecting a transgenic rescue
fragment containing the genomic locus of wild-type moag-4
intomoag-4mutant animals (Figures 1B and 1G). We then inves-
tigated whether a gain of function or inactivation ofmoag-4 was
responsible for suppressing aggregation. Both RNAi and genetic
deletion of moag-4(gk513), hereafter referred to as moag-4(del),
reduced the number of aggregates similar to mutant moag-4
(Figures 1F, 1H, and 1I). These results show that inactivation of
moag-4 suppresses the formation of polyglutamine aggregates.
MOAG-4 Acts Cell Autonomously on Protein
Aggregation
Known modifiers of protein aggregation include intracellular
mechanisms, involving protein folding and degradation, and
extracellular mechanisms, such as excitotoxicity (Behrends
et al., 2006; Garcia et al., 2007; Muchowski et al., 2000; Nollen
et al., 2004; Warrick et al., 1999; Zhai et al., 2008). If MOAG-4
acts intracellularly, expression of MOAG-4 only within the
same cells that express Q40::YFP should increase aggregation
in the moag-4 deletion strain. To test this possibility, we
expressed MOAG-4 from the unc-54 promoter in the moag-4
deletion strain, which drives expression to the same subset of
cells that express Q40::YFP. Expression of MOAG-4 in these
cells increased the number of aggregates (Figure 1J), showing
that MOAG-4 acts from within the cell.
MOAG-4 Drives Formation of Compact Misfolding
Intermediates
Having demonstrated that MOAG-4 acts intracellularly to modify
the formation of aggregates, we then investigated where
MOAG-4 acts in this process. We excluded the possibility that
aggregation was suppressed by MOAG-4 changing the
expression level from the transgene promoter, by showing that
wild-type Q40 animals or moag-4 mutants expressed similar
levels of YFP mRNA, protein, and polyglutamine-YFP proteins
from the same promoter (Figures 2A and 2B). Another possibility
is that MOAG-4 acts on an intermediate step in the aggregation
pathway. In this case, inactivating MOAG-4 should lead to the
accumulation of one or more aggregation intermediates. To
detect aggregation intermediates, we developed a native
agarose-gel electrophoresis (NAGE) assay. Lysates of moag-4
mutant and moag-4 deletion and wild-type polyglutamine
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Figure 1. Inactivation of MOAG-4
Suppresses Polyglutamine Inclusion Forma-
tion
(A) Number of aggregates inQ40, Q40;moag-4(pm),
and Q40;age-1(pm) mutant animals (L4 stage).
(B) Chromosomal location of the moag-4(Y37E3.4)
gene (http://www.wormbase.org, March 2010),
showing the location of the moag-4 point mutation
(pm), deletion (del), moag-4 RNAi fragment and
rescue fragment.
(C)Alignmentof theC.elegansMOAG-4proteinwith
representative orthologs from two eukaryotic king-
doms including fungi (yeast S. cerevisiae) and
diverse animal phyla, showing conservation of the
N-terminal domain and surrounding the M49I
substitution.
(D–F) Confocal images of Q40 animals with
wild-type, point mutant, or deletedmoag-4.
(G) Quantification of aggregates in Q40 animals and
Q40;moag-4(pm) animals, with and without trans-
genic overexpression of an injected moag-4
genomic locus rescue construct using the endoge-
nous moag-4 promoter (n = 13). NI denotes
noninjected.
(H) Quantification of aggregates in Q40 animals and
Q40;moag-4(pm) animals fed on control bacteria
containing empty RNAi vector (ctrl) and expressing
double-stranded RNA targetingmoag-4 (nR 10).
(I) Quantification of aggregates in Q40 animals with
wild-type, point mutant, or deletedmoag-4.
(J) Quantification of aggregates in Q40 animals and
Q40;moag-4(del) animals, with and without
transgenic overexpression of an injected moag-4
construct using the unc-54muscle promoter (n = 8).
In all panels, error bars represent the standard error
of the mean (SEM), *p < 0.0001, n.s. is nonsignifi-
cant; tests were one-tailed t tests. Aggregates
were quantified at the L4 larval stage, except for
Figure 1G, which was done in young adults. See
also Figure S1.animals were separated on a native agarose gel and the fluores-
cent molecules were visualized in gel by a fluorescence laser
scanner. This revealed a variety of differentially migrating protein
species in all Q40 animal lysates (Figure 2C), which were not
detected by western blot analysis of SDS-PAGE of the same
material. Also, no such forms could be observed in lysates of
Q0 or Q24 animals, indicating that the formation of these species
was specific for expanded polyglutamine (Figures 2C and 2D,
bands 1, 3–5, 6–7, and 8–9).
In order to further characterize these intermediates, we then
excised them from agarose gel after separation to analyze their
SDS solubility by SDS-PAGE followed by western blotting
(Figures 2E–2G). We combined this SDS-PAGE characterization
with quantifying the amount of fluorescence on NAGE. This
revealed that in the moag-4 mutants there was at least a 2-fold
decrease in a fraction that contained SDS-resistant aggregates
and that it was retained in the slots of the gel (Figures 2C and
2D and Figure S2, band 1). Furthermore, we observed a more
than 2-fold increase in two faster migrating SDS-soluble frac-
tions (bands 3–5 and 6–7) (Figures 2C–2G, Figure S2). Lastly,
and most prominently, in lysates of wild-type animals, a diffuse
band of fast-migrating SDS-sensitive formswas present (Figures2C, 2D, 2F, and 2G, bands 8–9 and Figure S2). This band was
reduced by 4-fold in lysates of moag-4 deletion strains (Figures
2C, 2D, and 2E, bands 8–9 and Figure S2). When extracted
from the agarose gel and run on an SDS-PAGE gel, these
species had the same size as the monomeric protein, which
excluded degradation as the reason for their fast migration on
the native agarose gel (Figure 2F, lanes 8 and 9). Alternatively,
the difference in migration could have been caused by a more
compact fold or a covalent modification that increased the net
negative charge of the protein. We excluded charge as a possi-
bility by showing that on a blue native gel, which hides the
inherent protein charge by nondenaturing binding of charged
Coomassie blue stain, this species still migrates faster than the
more abundant monomeric species (data not shown). Our data
therefore suggest that this band contains compact aggregation
intermediates. As this species was nearly absent in the moag-4
deletion strain, showing reduced aggregation, such compact
aggregation intermediates appear to be on a pathway prior to
aggregate formation. Together, these results suggest that the
presence of MOAG-4 drives aggregation-prone proteins toward
a compact conformation preceding the formation of aggregates
(Figure 2H).Cell 142, 601–612, August 20, 2010 ª2010 Elsevier Inc. 603
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Figure 2. Inactivation of MOAG-4 Suppresses the Formation of Compact Aggregation Intermediates
(A) Analysis of YFP, unc-54, sup-12, and act-4mRNA expression in Q40;moag-4(wt), Q40;moag-4(pm), and Q40;moag-4(del) animals. It shows PCR products of
cDNA dilutions (1:10, 1:20, and 1:50), aRT control, and a control without template for all genes. sup-12 served as a control for gene expression regulation at the
X-chromosomal level. Act-4 served as an internal expression control.
(B)Western blot analysis of denaturing SDS-PAGE separated protein lysates of Q0, Q24, Q35, andQ40with wild-type and pm allele for YFP expression usingGFP
antibody.
(C) Native agarose gel electrophoresis (NAGE) showing in-gel fluorescence of native species of YFP and YFP-polyQ fusions in young adult, whole-animal lysates.
(D) Graphical representation of fluorescence in native agarose gel depicted in (C) indicating four differentially migrating smears (bands 1, 3–5, 6–7, and 8–9).
RFI indicates relative fluorescence intensity.
(E–G) Fluorimetric scan of protein lysates of Q40 and Q40;moag-4(del) animals at day 6 separated by 1% NAGE, followed by separation of denatured agarose
fragments on SDS-PAGE and western blot analysis by probing with a GFP antibody.
(H) Model for the regulation of aggregation by MOAG-4: MOAG-4 drives the formation of compact misfolding intermediates that precede aggregate formation.
See also Figure S2.MOAG-4 Is Excluded from Polyglutamine Aggregates
To study where MOAG-4 acts in the cell, we expressedMOAG-4
fused to the red fluorescent protein mCherry (Cherry) from the
unc-54 promotor in the same cells in which Q40::YFP
is expressed. Expression of the fusion protein of the correct
size was confirmed by SDS-PAGE followed by western blotting
using MOAG-4-specific antibodies (Figure 3A). MOAG-4 fused
to cherry retained its function because animals expressing
MOAG-4::Cherry, and not Cherry or a fusion of Cherry to the
N terminus of MOAG-4, fully rescued the reduction in the
number of aggregates in the moag-4 deletion strain (Figure 3B).
MOAG-4::Cherry showed a diffuse expression pattern in the
cytosol and in cell nuclei (Figure 3C, MOAG-4::Cherry and604 Cell 142, 601–612, August 20, 2010 ª2010 Elsevier Inc.Figure S3). The localization of MOAG-4::Cherry was unaltered
in the presence of polyglutamine aggregates and MOAG-4 did
not colocalize with the aggregates (Figure 3C). These results
indicate that MOAG-4 may drive aggregation by acting on
soluble aggregation-prone proteins directly or by regulating
a signaling pathway.
Aggregation Suppression bymoag-4 Is Independent
of daf-16 and hsf-1
Suppression of aggregation in age-1mutant animals requires the
activities of both HSF-1 and DAF-16, which drive the expression
of molecular chaperones that suppress aggregation. We
addressed whether, similar to these IIS-compromised animals,
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Figure 3. MOAG-4::Cherry Is Excluded from Polyglutamine Aggregates
(A) Western blot analysis of protein lysates of Q40, Cherry, and MOAG-4::Cherry worms with peptide polyclonal antibodies against MOAG-4 and mouse
anti-actin.
(B) Quantification of the number of aggregates in Q40;moag-4(wt), Q40;moag-4(del), and animals transgenically expressing MOAG-4::Cherry, Cherry, or Cher-
ry::MOAG-4 (L4). ***p = 2*1012.
(C) Confocal images of red and green fluorescence andmerged images of Q40;moag-4(del), MOAG-4::Cherry, and double transgenic Q40;moag-4(del)3MOAG-
4::Cherry worms. Lower panels show enlargements of indicated area. See text for description of arrows.
Significance was calculated using two-tailed Student’s t test. In all panels, error bars represent SEM. See also Figure S3.suppression of aggregation by deletion of moag-4 required
HSF-1 and DAF-16 or their induced chaperones. We created
double-mutant animals containing the moag-4 deletion and an
inactivating mutation in hsf-1(sy441) (hsf-1(pm)) or a deletion in
daf-16(mu86) (daf-16(del)) or by depletion of hsf-1 or daf-16 by
RNAi. Loss of hsf-1 or daf-16 or both could not rescue suppres-
sion of aggregation by moag-4 deletion (Figures 4A and 4B).
We then asked whether chaperones that have been described
previously as influencing protein aggregation regulated the
suppression of aggregation in the moag-4 deletion strain
(Hsu et al., 2003; Morley and Morimoto, 2004; Nollen et al.,
2004). The expression of some of these chaperones is regulated
by HSF-1 and DAF-16. Knockdown of these chaperones by
RNAi did not rescue the suppression of aggregation in the strain
lacking moag-4 (Figures 4C and 4D). These results suggest that
MOAG-4 enhances aggregation either downstream or in parallel
to transcription factors and molecular chaperones that have
been described previously as influencing protein aggregation in
C. elegans.
SERF1A and SERF2 Drive Mutant Huntingtin
Aggregation in Human Neuroblastoma Cell Lines
We next tested whether the human orthologs of MOAG-4,
SERF1A and SERF2, also play a role in polyglutamine aggrega-tion. We addressed their influence on the toxicity and aggrega-
tion of a mutant huntingtin exon 1 fragment with 74 polyQ
repeats (Q74) in SK-N-SH neuroblastoma cells (Narain et al.,
1999). We used as a control a mutant huntingtin exon 1 fragment
with 23 polyQ repeats (Q23), which does not form aggregates.
Overexpression of SERF1A and SERF2 significantly increased
Q74 aggregation and increased cell death (Figures 5A and 5B).
Conversely, knockdown of either SERF1A or SERF2 in
HEK293 cells by RNAi decreased Q74 aggregation and
Q74-induced toxicity. Aggregation was suppressed without
altering the levels of polyglutamine expression, as SERF 1 or
SERF2 knockdown did not significantly alter the levels of the
wild-type huntingtin fragment (Figures S4B–S4). These effects
were also independent of autophagy and proteasomal degrada-
tion because overexpression of SERF1 or SERF2 increased
mutant huntingtin aggregation in both wild-type and autoph-
agy-deficient (Atg5/) mouse embryonic fibroblasts
(Figure 5D) and SERF1 and SERF2 overexpression did not affect
the accumulation of the specific ubiquitin-proteasome substrate
UbG76V-GFP (Figure 5D) or wild-type huntingtin fragment
(Figure S4A). Thus, humanSERF proteins regulate polyglutamine
aggregation in a similar manner toMOAG-4, which indicates that
this aggregation-promoting function has been evolutionarily
conserved from worms to humans.Cell 142, 601–612, August 20, 2010 ª2010 Elsevier Inc. 605
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Figure 4. Aggregation Suppression by
MOAG-4 Is Independent of DAF-16, HSF-1,
and Chaperones
Quantification of the number of aggregates in L4
larvae.
(A) Aggregates in Q40, Q40;moag-4(del), Q40;daf-
16(del), Q40;moag-4(del);daf-16(del), Q40;hsf-1
(pm), and Q40;moag-4(del);hsf-1(pm) (n = 40).
Significance was calculated using one-tailed
unpaired t test.
(B) Aggregates in Q40, Q40;moag-4(del), and
Q40;daf-16(del) fed for two generations on control,
hsf-1, and daf-16 RNAi foods.
(C and D) Aggregates in Q40 on control RNAi and
Q40;moag-4(del) on control RNAi and RNAi
targeting the indicated chaperones that have
been described previously to modify polyglut-
amine aggregation in C. elegans.
In all panels, error bars represent SEM. Signifi-
cance was calculated using two-tailed Student’s
t test. Asterisks indicate a significant increase in
aggregation compared to control RNAi (Bonferroni
corrected p value < 0.05). As an internal quality
control for RNAi, squares indicate the penetrance
(<50% [open] and > 50% [filled]) of all associated
visible RNAi phenotypes other than aggregation.Loss ofmoag-4 Suppresses Toxicity of Polyglutamine
in C. elegans
Expression of expanded polygutamine in C. elegans body-wall
muscle cells is toxic, as measured by a progressive decline in
the motility of the animals during aging (Morley et al., 2002).
To investigate if MOAG-4 plays a role in polyglutamine toxicity,
we measured the motility of age-synchronized animals
expressing Q40::YFP with or without moag-4. The toxicity
of Q40::YFP from day 12 onward was suppressed in the
moag-4 deletion animals (Figure 6A, p < 0.05). These results
suggest that the presence of MOAG-4 enhances the toxicity
of polyglutamine.
Loss ofmoag-4 Suppresses Aggregation and Toxicity
of Amyloid-Beta and Alpha-Synuclein
To determine whether MOAG-4 is a more general regulator of
proteotoxicity or whether its actions are specific for aggrega-
tion-prone polyglutamine proteins, we investigated the effects
of moag-4 inactivation in C. elegans models for aggregation of
human amyloid-beta peptide (Ab1–42), alpha-synuclein, and
mutant SOD1.
Ectopic expression of the human amyloid-beta peptide
(Ab1–42) in the muscle cells of C. elegans results in the formation
of amyloidogenic aggregates and a progressive paralysis of the
worms (Link, 1995). Deletion ofmoag-4 in Ab1–42 worms resulted
in a decrease of more than 40% in the fraction of paralyzed
worms over a 12 day time course (Figure 6B). To address
whether suppression of paralysis in moag-4 deletion worms
was accompanied by an alteration in the amount of Ab1–42 seed-
ing-competent (fibrillar) aggregates, we used an in vitro kinetic
aggregation assay (Cohen et al., 2006). This assay measures
the aggregation kinetics of purified Ab1–40 peptides, which
depends on the amount of fibrillar seeding that is present in
sonicated lysates of Ab1–42 expressing worms. Lysates of606 Cell 142, 601–612, August 20, 2010 ª2010 Elsevier Inc.wormswith amoag-4 deletion seeded Ab1–40 aggregation signif-
icantly slower than lysates of wild-type Ab1–42 worms (t50 = 30 hr
versus t50 = 17 hr, p < 0.05), indicating that moag-4 deletion
worms contained fewer seeding-competent fibrillar Ab1–42
aggregates (Figure 6C). In addition, SDS-PAGE analysis of soni-
cated lysates of themoag-4 deletion strain showed an alteration
in the relative size distribution of Ab1–42 oligomers compared to
wild-type worms, without lowering the total amount of Ab1–42
(Figure 6D and Figure S5A). In particular, subsets of the highest
as well as the lowest molecular weight species, which were
abundant in the wild-type lysates, were nearly absent in the
moag-4 deletion lysates, which was compensated by an
increase in intermediate size oligomeric forms. Together, these
results suggest that the activity of MOAG-4 normally leads
to an increase in the formation of amyloidogenic conformers
of Ab1–42.
Expression of YFP-tagged human alpha-synuclein or mutant
human SOD in C. elegans muscle cells results in an age-
dependent formation of inclusions (Gidalevitz et al., 2009; van
Ham et al., 2008). Expression of alpha-synuclein and SOD in
these worms resulted in an age-dependent and progressive
decline in motility (Figures 6E and 6H) (Gidalevitz et al.,
2009). Deletion of moag-4 suppressed the toxicity of alpha-
synuclein from day 4 onward (p < 0.05) but had no influence
on the toxicity of mutant SOD (Figures 6E and 6H). Similarly,
although deletion of moag-4 did reduce the number of alpha-
synuclein-YFP inclusions by 30% (p < 0.01) without affecting
the amount of alpha-synuclein-YFP expression in the worms
(Figures 6F and 6G, Figure S5B), it had no effect on the
number of inclusions in mutant SOD worms (Figure 6J and
Figure S5C). In all, our results suggest that MOAG-4 is
a general regulator of protein aggregation and proteotoxicity
but it does not act on all disease-associated aggregation-
prone proteins.
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Figure 5. Human SERF1A and SERF2 Modu-
late the Aggregation and Toxicity of Mutant
Huntingtin in Neuronal Cell Lines
(A) SK-N-SH cells transiently transfected with
SERF1A or SERF2, or control (dsRed2), and
HA-tagged huntingtin exon 1 (Q74) (at a 3:1 ratio)
for 24 hr were labeled with anti-HA antibody to
detect Q74. Q74-expressing cells with aggregates
are marked by arrows.
(B) Percentage of Q23- and Q74-transfected
SK-N-SH cells showing aggregation and cell death
after transient transfection with SERF1A or SERF2,
or control (dsRed2), and HA-tagged huntingtin
exon 1 (Q23 or Q74) (at a 3:1 ratio) for 24 hr.
(C) Representative experiment of Q74 aggregation
and cell death in HEK293 cells transiently trans-
fected with siRNA targeting SERF1A or SERF2,
or a nontargeting siRNA as control, and HA-tagged
huntingtin exon 1 (Q74) for 48 hr. Statistics were
performed by calculating odds ratios frommultiple,
independent triplicate experiments (see Experi-
mental Procedures) ***p < 0.001; **p < 0.01;
*p < 0.05.
(D) Percentage of transfected cells showing Q74
aggregation in Atg5+/+ (wild-type) or Atg5/
(Atg5 knockout) MEF cells after transient transfec-
tion with SERF1A or SERF2, or control (dsRed2),
and HA-tagged huntingtin exon 1 (Q74) (at a
3:1 ratio) for 48 hr. Statistics were performed by
calculating odds ratios from multiple, independent
triplicate experiments (see Experimental
Procedures).
(E) UbG76V-GFP levels in HeLa cells stably trans-
fected with UbG76V-GFP after transient transfec-
tion with SERF1A or SERF2, or control (dsRed2).
MG132 (proteasome inhibitor) treatment for 24 hr
was used as control.
In all panels, error bars represent SEM. See also
Figure S4.Regulation of Aggregation by MOAG-4 Is Independent
of Life Span
Knowing that inactivation of age-1 suppresses polyglutamine
aggregation and prolongs life span, we then askedwhether inac-
tivation ofmoag-4would also affect life span. Wemeasured over
time the survival of age-synchronized wild-type-, age-1 mutant,
and moag-4 mutant animals. Animals with a point mutation in
moag-4, which suppresses aggregation to a similar extent as
themoag-4 deletion, do not show an effect on life span (Figure 7).
These results provide evidence that the aggregation regulatory
activities of moag-4 are uncoupled from life-span regulation.
DISCUSSION
Fibrillar aggregates are thought to arise from toxic aggregation-
prone proteins when the activities of other protein quality control
mechanisms decline or are functionally impaired, which may
occur during aging or in disease (Kaganovich et al., 2008;
Williams and Paulson, 2008). Here we describe a previously
unidentified modifier, MOAG-4, as a positive regulator of
aggregate formation in C. elegans and human cell models for
neurodegenerative disease. In animals expressing polyglut-amine, MOAG-4 induces a conformational change in aggrega-
tion-prone proteins preceding the formation of aggregates.
We have identified MOAG-4 as a regulator of proteotoxicity in
transgenic disease models. The natural function of MOAG-4 in
the absence of these exogenous proteins remains to be investi-
gated, but we would like to propose three possible functions.
One possibility is that MOAG-4 acts as an inhibitor of a stress-
response pathway, similar to the IIS pathway, and that deletion
of MOAG-4 induces the expression of downstream targets that
suppress proteotoxicity (Cohen et al., 2006, 2009; Hsu et al.,
2003; Morley and Morimoto, 2004). As suggested by our find-
ings, these targets would then be induced independently of the
IIS transcription factors DAF-16 and HSF-1. Moreover, these
targets would involve a different subset than those that have
previously been described to suppress proteotoxicity, indicating
that MOAG-4 would act through a previously unexplored stress-
response pathway.
Second, MOAG-4 could act positively on aggregation, either
as a component of a pathway or by direct interaction with the
aggregation-prone proteins. For example, MOAG-4 may nor-
mally act in an endogenous amyloid pathway, such as the one
that is used for hormone peptide storage and secretionCell 142, 601–612, August 20, 2010 ª2010 Elsevier Inc. 607
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Figure 6. Deletion of moag-4 Suppresses
Aggregation and Proteotoxicity in C. ele-
gans Models for Polyglutamine Disorders,
Alzheimer’s Disease, and Parkinson’s
Disease
(A) Number of body bends per minute in Q24, Q40,
and Q40;moag-4(del) animals, measured over
time. n = 15 and bars represent the normalized
average of three independent experiments.
(B) The percentage of paralyzed Ab1–42 and
Ab1–42;moag-4(del) animals was measured during
12 consecutive days. One of three independent
experiments is displayed. Measurements repre-
sent means ± SEM.
(C) Ab1–40 kinetic aggregation assay performed
with CL2006 (Aß-expressing worm) and OW440
(moag-4 deletion mutant worm). Ab1–40 (10 mM)
kinetic aggregation traces with post-debris super-
natant (PDS) of CL2006 and OW440. The concen-
tration of total proteins was 25 mg/ml in the final
kinetic aggregation assay. Inset: comparison of
t50 values. Data are reported as mean ± standard
deviation (SD) of four different biological replicates.
(D) Western blot analysis of PDS of CL2006 and
OW440. Worms were harvested at day 1 of adult-
hood to make PDS. Two hundred micrograms of
protein from each sample was loaded to 4%–
12% SDS-PAGE gel to detect amyloid-beta and
alpha-tubulin.
(E) Number of body bends per minute in YFP, asyn,
and asyn;moag-4(del) animals, measured over
time. n = 10 for each experiment and bars repre-
sent the average of three independent experi-
ments, except for day 10, which represents
10 animals in total.
(F) Number of inclusions in asyn and asyn;moag-4
(del) animals at day 1 of adulthood (n = 20).
(G) Confocal images of asyn and asyn;moag-4(del)
animals.
(H) Number of body bends per minute in SODwt,
SODG93A, and SODG93A;moag-4(del) animals,
measured over time. n = 15 for each experiment
except for day 16, which represents at least 18 in
total, and bars represent the average of three inde-
pendent experiments.
(I) Number of inclusions in SODG93A and
SODG93A;moag-4(del) animals at day 1 of adult-
hood.
(J) Confocal images of SODG93A and SODG93A;-
moag-4(del) animals (n = 20).
In all panels, error bars represent SEM. *p < 0.05;
**p < 0.01; ***p < 0.001. See also Figure S5. Signif-
icance of body bend experiments was calculated
using two-tailed Student’s t test(Maji et al., 2009). Aggregation-prone disease proteins could
then be anomalously recognized as targets and hijack this
hormone peptide storage and secretion system and cause
toxicity from within or from outside the cell.
Finally, MOAG-4 could be part of a quality control pathway
that drives toxic, aggregation-prone proteins into aggregates
for storage (Kaganovich et al., 2008). Increased proteotoxic
stress, such as the constitutive presence of aggregation-prone
disease proteins, may saturate this pathway and lead to the
accumulation of toxic intermediates. Our finding that MOAG-4608 Cell 142, 601–612, August 20, 2010 ª2010 Elsevier Inc.is involved in the formation of such aggregation intermediates
would then explain why loss of MOAG-4 suppresses toxicity.
Further studies are needed to explore these and other possible
mechanisms.
Previously, other factors have been identified that enhance
polyglutamine protein aggregation. These include the SH3-
domain GRB2-like 3 (SH3GL3) and the G protein-coupled
receptor kinase interacting-protein 1 (GIT1), which act by an
unknown mechanism, and components of the microtubule
network that is thought to be involved in transport of
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Figure 7. C. elegans Strain with a Point
Mutation inmoag-4 Has a Normal Life Span
(A) Longitudinal survival (20C) of Q40, Q40;age-1
(pm), age-1(pm), and Q40;moag-4(pm) animals.
(B) Statistical analysis of longitudinal survival of
Q40, Q40;age-1(pm), age-1(pm), and Q40;moag-
4(pm) animals. ns, not significant.aggregation-prone proteins toward aggregates (Goehler et al.,
2004; Muchowski et al., 2002; Sittler et al., 1998). It will be inter-
esting to establish how MOAG-4 functionally relates to these
modifiers.
The human orthologs of MOAG-4, SERF2 and SERF1A, are
ubiquitously expressed, consistent with a role in a general
cellular pathway. SERF1A was first identified as a genetic modi-
fier of spinal muscular atrophy (SMA), but its function and how it
enhances the severity of this disease is still unknown (Scharf
et al., 1998). Based on our findings that these human orthologs
of MOAG-4 similarly modify protein aggregation, it is possible
that protein misfolding plays a role in enhancing the SMA pheno-
type.
In all, the moag-4 gene is part of a pathway regulating age-
related proteotoxicty. Further exploration of this pathway will
broaden our understanding of how cells cope with the constant
challenges on protein stability imposed by intracellular and
extracellular environmental perturbations and in disease.
Furthermore, as deletion ofmoag-4 does not affect the viability
of the organism and SERF2 and SERF1 are evolutionarily highly
conserved human orthologs of moag-4, this pathway may
provide a new target for therapeutic intervention in the early
molecular events of aging-associated neurodegenerative
diseases. Our findings suggest that, apart from activating HSF-
1-regulated molecular chaperones, proteasomal degradation,
or autophagy, an alternative strategy to ameliorate the toxic
effects of aggregation-prone proteins in disease could be to
intervene in this pathway.
EXPERIMENTAL PROCEDURES
Media and Strains
Standard conditions were used for C. elegans propagation at 20C
(Brenner, 1974). Animals were synchronized by hypochlorite bleaching,
hatched overnight in M9 buffer, and subsequently cultured on NGM agar
plates seeded with OP50. On day 3 after synchronization, animals were placed
on NGM plates containing 5-Fluoro-20deoxy-uridine (FUDR) to inhibit growthCell 142, 601–612of offspring. The strains used or generated are
described in the Extended Experimental Proce-
dures.
Creation of Transgenic Strains
Microinjection was used to create new transgenic
strains as described. Unless mentioned otherwise,
animals were outcrossed to N2 at least four times.
EMS Mutagenesis and Mapping
Mutagenesis was performed using standard
C. elegans ethyl methanesulfonate (EMS) meth-
odology (Jorgensen andMango, 2002). Eight thou-
sand mutagenized genomes were screened for
suppressors of aggregation. moag-4(pk2185)was identified by single-nucleotide polymorphism (SNP) mapping (Wicks
et al., 2001) to a region between base 1,983,175 and 2,080,838 on linkage
group I. All exons of 16 remaining candidate genes in that region were
sequenced to identify the mutation in Y37E3.4. Suppression of aggregation
was rescued by reintroduction into NL4436 of a genomic construct spanning
1 kb upstream to 300 bp downstream of the Y37E3.3, Y37E3.4, and
Y37E3.5 containing operon. The operon was amplified by nested PCR and
was coinjected with pJKL449.1[P(myo-2::GFP)] as a coinjection marker.
RNA Isolation and Reverse Transcriptase PCR
Total RNA was extracted from L4 synchronized animals using Trizol reagent
(Invitrogen, Breda, the Netherlands) according to the manufacturer’s instruc-
tions. cDNA was made from 2 mg total C. elegans RNA using Ready-To-Go
First Strand Synthesis Beads (GE Healthcare, Leiderdorp, The Netherlands),
including a control without reverse transcriptase (-RT) for all strains indicated.
Serial dilutions of the cDNA (1:10, 1:20, and 1:50) and the -RT control were
amplified using PCR with cycle numbers varying between 25 and 31 for
optimal detection of the PCR product. Samples were run on 2.5% agarose-
gels stained with ethidium bromide, imaged with a UV scanner, and analyzed
using Image J software.
Quantification of Aggregates
The number of aggregates present in whole animals was counted using
a fluorescence dissection stereomicroscope (Leica Microsystems, Wetzlar,
Germany) at a nominal magnification of 1003. At least twenty animals were
counted, unless stated otherwise. Microsoft Excel Student’s t test was used
to calculate p values. All testswere two-tailed unpaired unless otherwise stated.
Immunoblotting Analysis
C. elegans protein extracts were prepared from whole animal frozen pellets in
PBS containing proteinase inhibitors (Roche, Indianapolis, USA) by using Fast-
prep24 (MP, Solon, USA). Samples were boiled for 5 min with sample buffer
containing SDS and DTT and separated using 10% SDS-PAGE. Proteins
were transferred to PVDFmembranes by semi-dry blotting. Primary antibodies
used were anti-GFP (monoclonal [JL-8], polyclonal [full-length GFP, Clontech,
Mountainview, CA, USA]), anti-RFP (polyclonal, Clontech), anti-tubulin (mono-
clonal B-5-1-2, Sigma Aldrich, St. Louis, MO, USA), anti-actin (monoclonal C4,
MP Biomedicals), and custom-made polyclonal peptide antibodies against
MOAG-4. Goat anti-mouse and goat anti-rabbit IgG-HRP (BioRad, Hercules,
CA, USA) were used as secondary antibodies. Antibody bindingwas visualized
by chemiluminescence (ECL Lumi-Light, Roche, Germany)., August 20, 2010 ª2010 Elsevier Inc. 609
Protein Separation on Agarose Gel
Native protein extract was loaded with native loading buffer (working concen-
tration of 0.0625M tris, 10%glycerol, and bromophenol blue) on horizontal 1%
agarose gel (running buffer 25 mM tris, 0.19 M glycine [pH 8.3]). Gels were run
for 14 hr at 4C and analyzed using a laser scanner (Molecular imager FX, Bio-
Rad) with excitation at 488 nm and detection of emission at 530 nm. Image
analysis was performed using ImageJ software. Excised agarose fractions
were denatured and liquefied by boiling in SDS sample buffer containing
DTT and loaded on SDS-PAGE gel while liquid for subsequent western blot-
ting. Quantification of different protein species were calculated as means of
three independent experiments. Error bars represent standard error of the
mean (SEM).
In Vitro Ab1–40 Kinetic Aggregation Assay with Worm PDS
Sonicated post-debris supernatant (PDS) of wormswasmixed withmonomer-
ized synthetic Ab1–40 peptide to a final concentration of 10 mM in phosphate
buffer (50 mM Na-phosphate, 150 mM NaCl, pH 7.4) containing ThT
(20 mM). Aliquots (100 ml) in a 96-well microplate (Costar black, clear bottom)
were read with a TECAN fluorescence microplate reader (Tecan Group Ltd)
at 37C. Half-maximal fluorescence time points (t50) were defined as the
time point at which ThT fluorescence reached the midpoint between pre-
and post-aggregation baselines (see also Extended Experimental Procedures
for a detailed description).
Confocal Laser Scanning Microscopy
Transgenic animals were mounted on 2% agarose pads containing 40 mM
NaN3 as anesthetic on glass microscope slides. Fluorescence images were
captured with a confocal microscope (TCS SP2 AOBS or SOLAMERE, and
Leica Microsystems, Mannheim, Germany) using a 403 oil immersion
objective (HCX PL APO CS, Leica). Images shown are maximal projections
of Z stacks.
Life-Span Assays
Life-span assays were carried out by growing L4 stage synchronized animals
on NGMagar plates containing FUDR. Animals were grown at 20C. Life spans
were started from 100 L4 stage animals per strain on FUDR-containing agar
plates seeded with OP50 and allowed to grow at 20C. At each time point,
the number of surviving animals was counted, as determined by movement
and response to nose touch. Animals that disappeared during the assay or
crawled out of the plates were excluded. Analysis was performed usingGraph-
pad Prism (GraphPad Software, San Diego, CA, USA).
Motility Assay
At different ages, animals were placed in a drop of M9 and were allowed to
recover for 1 min after which the number of body bends was counted for
1 min. At least 12 animals were counted per experiment, unless stated other-
wise, and the data from three independent experiments were combined.
Statistical analyses were performed in Graphpad Prism (GraphPad Software)
(Gidalevitz et al., 2009).
Paralysis Assay
Paralysis assays were performed by growing L4 stage synchronized animals
on agar plates containing FUDR. To avoid developmental defects of the vulva,
animals were grown at 15C until the first day of adulthood, after which they
were moved to 20C. Each individual experiment was started from 100
L4 stage animals per strain. Animals were tested every day for 12 consecutive
days for paralysis by tapping their noses and tail-prodding with a platinumwire
as described previously (Cohen et al., 2006). Worms that moved their noses
but failed to move their bodies were scored as ‘‘paralyzed.’’ Analysis was
performed using Graphpad Prism (GraphPad Software).
RNAi Experiments
RNAi experiments were performed on NGM agar plates containing 1mM IPTG
and 50 mg/ml ampicillin that were seeded with RNAi bacteria induced with
IPTG to produce dsRNA. Animals synchronized by hypochlorite bleaching
were grown on RNAi plates and used for the experiments. The RNAi clones610 Cell 142, 601–612, August 20, 2010 ª2010 Elsevier Inc.used were verified by sequencing the insert using L4440 primers and
subsequent BLAST analysis to confirm the correct sequence.
Mammalian Cell Culture
Human neuroblastoma cell line (SK-N-SH), human embryonal kidney cell line
(HEK293), and wild-type Atg5 (Atg5+/+) and Atg5-deficient (Atg5/) mouse
embryonic fibroblasts (MEFs) (kindly given by N. Mizushima) were maintained
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum, 100 units/ml penicillin/streptomycin, and 2 mM L-glutamine (Sigma) at
37C, 5% CO2 (Mizushima et al., 2001).
Cells were transfected using Lipofectamine or reagent (Invitrogen)
according to themanufacturer’s protocol and fixedwith 4%paraformaldehyde
(Sigma) after 24–48 hr post-transfection, HA-HDQ74 and HA-HDQ23
expression detected using an anti-HA antibody (12CA5, Covance) and fluoro-
phore-conjugated secondary antibody (Alexa Fluor [green] anti-mouse;
Molecular Probes), and mounted in Citifluor (Citifluor Ltd.) containing 40,6-dia-
midino-2-phenylindole (DAPI; 3 mg/ml; Sigma-Aldrich).
Quantification of Aggregate Formation and Cell Death
Aggregate formation and nuclear morphology were assessed using a fluores-
cencemicroscope. Double-expressing cells with both red (SERF proteins) and
green (HA-tagged HDQ74 or HDQ23) fluorescence were scored for cell death
and aggregation. Approximately 200 cells per coverslip were selected and the
number of cells with aggregates was counted. The experiments were per-
formed blinded and in triplicate and repeated at least twice. Cells were consid-
ered dead if the DAPI-stained nuclei showed apoptotic morphology (fragmen-
tation or pyknosis).
RNA Interference in Human Cells
HEK293 cells were transfectedwith HA-HDQ74 alongwith SERF1A, SERF2, or
nontargeting siRNA as control (Dharmacon, cat. no. D-001210-01) for 48 hr
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol.
The final siRNA concentration was 50 nM. Cells were fixed after transfection,
immunolabeled, and analyzed by fluorescence microscopy.
Pooled estimates for changes in aggregate formation or cell death resulting
from perturbations assessed in multiple experiments were calculated as odds
ratios (OR; the ratios of the proportion of abnormal/normal cells in different
experimental conditions) with 95% confidence intervals as described
(Wyttenbach et al., 2001). Significance levels for comparisons between groups
were determined with t tests.
Bioinformatic Analysis
Orthologs were identified using protein BLAST search and aligned with
T-Coffee multiple sequence alignment tool (Notredame et al., 2000).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
2010.07.020.
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